Pharmaceutical - Anti-virals, Research

Filter

Current filters:

Anti-viralsResearch

Popular Filters

1 to 25 of 100 results

Hera Therapeutics’ HTI-1968 shuts down HPV that causes most cervical cancer

Hera Therapeutics’ HTI-1968 shuts down HPV that causes most cervical cancer

23-08-2014

Research presented at the 29th Annual International Papillomavirus Conference shows that a therapy being…

Anti-viralsHera Therapeuticshti-1968PharmaceuticalResearchWomen's Health

Animal data show positive results in Marburg virus with Tekmira’s LNP

Animal data show positive results in Marburg virus with Tekmira’s LNP

21-08-2014

Canadian RNA interference (RNAi) therapeutics developer Tekmira Pharmaceuticals has highlighted the publication…

Anti-viralsPharmaceuticalResearchTekmira PharmaceuticalsTKM-Ebola

Achillion soars on positive mid-stage hep C drug combo trial

Achillion soars on positive mid-stage hep C drug combo trial

17-08-2014

US drugmaker Achillion saw its share rocket 18.4% to a 52-week high of $9.99 in pre-market trading on…

ACH-3102AchillionAnti-viralsHepatitis C virusPharmaceuticalResearchsofosbuvirSovaldiUSA

Sanofi Pasteur announces positive results for Fluzone’s higher dose

Sanofi Pasteur announces positive results for Fluzone’s higher dose

14-08-2014

Sanofi Pasteur, the vaccines division of French drug major Sanofi, has found that Fluzone High-Dose was…

Anti-viralsFluzonePharmaceuticalResearchSanofiSanofi PasteurUSAVaccinationVaccines

FDA modifies Tekmira's TKM-Ebola clinical hold to partial hold

FDA modifies Tekmira's TKM-Ebola clinical hold to partial hold

08-08-2014

Canadian RNA interference (RNAi) therapeutics developer Tekmira Pharmaceuticals revealed yesterday that…

Anti-viralsEbolaMicrobiologyPharmaceuticalRegulationResearchTekmira PharmaceuticalsTKM-EbolaUS Food and Drug AdministrationUSA

Biota tanks as flu drug candidate disappoints

Biota tanks as flu drug candidate disappoints

04-08-2014

USA-based Biota Pharmaceuticals saw its shares slump 29% to a record low of $2.29 on Friday, after the…

Anti-viralsAntibiotics and Infectious diseasesBiota PharmaceuticalsFinancialPharmaceuticalResearchUSA

Janssen’s simeprevir for hepatitis C shows good efficacy in Phase II trial

Janssen’s simeprevir for hepatitis C shows good efficacy in Phase II trial

31-07-2014

Some 92% of genotype 1 chronic hepatitis C virus (HCV) adult patients treated with US health care giant…

Anti-viralsGilead SciencesIrelandJanssenPharmaceuticalResearchsimeprevirsofosbuvir

Novartis’ Bexsero has high uptake in first widespread public vaccination program against meningitis B

Novartis’ Bexsero has high uptake in first widespread public vaccination program against meningitis B

29-07-2014

Swiss drug major Novartis has announced initial results from a large-scale vaccination campaign using…

Anti-viralsBexseroCanadaMeningitis BNovartisPharmaceuticalResearch

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

03-07-2014

USA-based Isis Pharmaceuticals has earned yet another $1 million payment from UK pharma giant GlaxoSmithKline,…

Anti-viralsFinancialGlaxoSmithKlineIsis PharmaceuticalsPharmaceuticalResearch

Boehringer Ingelheim pulls out of hepatitis C drug development

Boehringer Ingelheim pulls out of hepatitis C drug development

23-06-2014

German family-owned pharma major Boehringer Ingelheim revealed that, following a re-evaluation of its…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalRegulationResearch

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

12-06-2014

ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland, a…

Anti-viralsEdurantGlaxoSmithKlineJanssenJohnson & JohnsonLicensingPharmaceuticalResearchTivicayViiV Healthcare

PaxVax signs R&D deal with UC San Diego to develop herpes vaccine

PaxVax signs R&D deal with UC San Diego to develop herpes vaccine

11-06-2014

Privately-held California, USA-based specialty vaccine firm PaxVax has entered into a research and development…

Anti-viralsLicensingPaxVaxPharmaceuticalResearchVaccines

Janssen expands accord with IPM for dapivirine in prevention of sexual transmission of HIV

08-05-2014

Janssen R&D Ireland, a unit of US health care giant Johnson & Johnson, has expanded its collaboration…

Anti-viralsJanssenJohnson & JohnsonPharmaceuticalResearch

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

14-04-2014

US drugmaker AbbVie has revealed promising new results from its hepatitis C development program at the…

AbbVieAnti-viralsPharmaceuticalResearchUSA

Bristol-Myers’ all-oral daclatasvir and asunaprevir combo shines in Ph III

Bristol-Myers’ all-oral daclatasvir and asunaprevir combo shines in Ph III

10-04-2014

US pharma major Bristol-Myers Squibb has presented new Phase III trial data of its combination therapy…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirPharmaceuticalResearch

Promising results for Merck & Co’s hepatitis C drug combo

Promising results for Merck & Co’s hepatitis C drug combo

10-04-2014

US pharma giant Merck & Co has announced additional data from the ongoing C-WORTHy study, a multi-arm…

Anti-viralsMerck & CoMK-5172PharmaceuticalResearch

Positive new Ph III data from once-daily simeprevir presented at APASL

18-03-2014

Encouraging new Phase III data for the once-daily protease inhibitor simeprevir (trade name Olysio in…

Anti-viralsJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalResearchsimeprevir

Positive new results for Merck’s Isentress in HIV-1 presented at CROI 2014

Positive new results for Merck’s Isentress in HIV-1 presented at CROI 2014

07-03-2014

USA pharma giant Merck & Co subsidiary MSD says that in a 96-week, open-label AIDS Clinical Trials Group…

Anti-viralsIsentressMerck & CoPharmaceuticalResearch

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

06-03-2014

German family-owned pharma major Boehringer Ingelheim announced positive results from STARTVerso 4 in…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalRegulationResearch

IN FOCUS: Viiv Healthcare’s Tivicay offers new HIV treatment option for patients

IN FOCUS: Viiv Healthcare’s Tivicay offers new HIV treatment option for patients

03-02-2014

Global HIV company Viiv Healthcare has launched its first new treatment option for people with HIV today.

Anti-viralsAtriplaInterviewsIsentressPharmaceuticalPrezistaRegulationResearchTivicayUKViiV Healthcare

Janssen sets up new group targeting unmet global health needs

Janssen sets up new group targeting unmet global health needs

22-01-2014

US health care giant Johnson & Johnson’s Janssen companies are forming Janssen Global Public Health,…

Anti-viralsAntibiotics and Infectious diseasesJanssenJohnson & JohnsonPharmaceuticalResearch

1 to 25 of 100 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top